The Advisory Board is appointed by and report to the Board of Directors of the Corporation.
The Board has sought individuals based on their unique knowledge, and expertise, either in business affairs generally or the Corporation’s industry in particular, who are capable of making a valuable contribution to the Corporation’s business.
The Role of the Advisory Board is solely advisory in nature. Our Advisors are:
From September 2008 to March 2013, Mr. Pelzer served as the President of Novartis Corporation, a pharmaceutical company. From 2002 to 2008, he served as General Counsel at Novartis Pharma AG. Prior to 2002, Mr. Pelzer held various positions at DuPont, including serving as General Counsel and Senior Vice President at DuPont Pharmaceuticals from 1998 to 2001. Mr. Pelzer currently serves on the board of directors of Aquinox Pharmaceuticals, Inc. and previously served on the board of directors of Idenix Pharmaceuticals, Inc. Mr. Pelzer holds a BCom and an LL.B. from the University of Alberta.
Dr. Peter Johann is the Founder, Chairman & CEO of Lumendi Ltd, an innovative Medtech company focusing on devices enabling endoluminal interventions. He is a Managing General Partner of NGN Capital, a healthcare venture capital investor and has had several successful IPOs and M&A transactions in his investment portfolio. He currently serves on the Board of Directors of Noxxon Pharma AG, Vivaldi Biosciences Inc. and Exosome Diagnostics Inc.
Prior to NGN he held several positions in the healthcare industry. He was the Division Head of Corporate Development at Boehringer Ingelheim where he was responsible for strategic planning, strategic projects, M&A, business development and licensing. Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader Oncology Products, at Boehringer Mannheim as Head of Business Development and Marketing Molecular Medicine and had Marketing, Sales and Business Development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of Biopharmaceuticals.